Search Result

Results for "

metastatic breast cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) ADC Cytotoxin (1) Antibiotic (1) Apoptosis (7) Aurora Kinase (1) Autophagy (1) Bacterial (1) Cathepsin (1) CX3CR1 (2) CXCR (2) Discoidin Domain Receptor (1) DNA Stain (1) E1/E2/E3 Enzyme (1) EGFR (7) Estrogen Receptor/ERR (3) FGFR (1) HDAC (2) MAP3K (1) MDM-2/p53 (1) Microtubule/Tubulin (3) PERK (1) PKC (1) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (1) STAT (1) TGF-β Receptor (1) VD/VDR (1) Wnt (1)
By Research Areas:	Cancer (33) Endocrinology (3) Infection (2) Inflammation/Immunology (5) Metabolic Disease (1)

By Targets:

ADC Antibody (2)

ADC Cytotoxin (1)

Antibiotic (1)

Apoptosis (7)

Aurora Kinase (1)

Autophagy (1)

Bacterial (1)

Cathepsin (1)

CX3CR1 (2)

CXCR (2)

Discoidin Domain Receptor (1)

DNA Stain (1)

E1/E2/E3 Enzyme (1)

EGFR (7)

Estrogen Receptor/ERR (3)

FGFR (1)

HDAC (2)

MAP3K (1)

MDM-2/p53 (1)

Microtubule/Tubulin (3)

PERK (1)

PKC (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Reactive Oxygen Species (1)

STAT (1)

TGF-β Receptor (1)

VD/VDR (1)

Wnt (1)

By Research Areas:

Cancer (33)

Endocrinology (3)

Infection (2)

Inflammation/Immunology (5)

Metabolic Disease (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Targets Recommended: BCRP BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13442

Eribulin 4 Publications Verification B1939; E7389; ER-086526	Microtubule/Tubulin Apoptosis ADC Cytotoxin	Cancer
Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.

HY-13442A

Eribulin mesylate 4 Publications Verification B1939 mesylate; E7389 mesylate; ER-086526 mesylate	Microtubule/Tubulin Apoptosis	Cancer
Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.

HY-P99030

Margetuximab	EGFR	Cancer
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

HY-136244

PF-06952229 1 Publications Verification	TGF-β Receptor	Cancer
PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction. PF-06952229 is a promising antineoplastic agent for the study solid tumors, especifically metastatic breast cancer .

HY-P99437

Anbenitamab 1 Publications Verification KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .

HY-P9907

Trastuzumab Maximum Cited Publications 33 Publications Verification Anti-Human HER2, Humanized Antibody	Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody	Cancer
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9907A

Trastuzumab (anti-HER2) Maximum Cited Publications 33 Publications Verification Anti-Human HER2, Humanized Antibody (PBS)	ADC Antibody EGFR	Cancer
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-N1823

Pygenic acid A	Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Pygenic acid A is a natural compound that can be found in Prunella vulgaris. Pygenic acid A induces apoptosis in metastatic breast cancer cells. Pygenic acid A can be used for the research of diabetes, inflammatory diseases, and cancers .

HY-139376

FGFR1 inhibitor-2	FGFR	Cancer
FGFR1 inhibitor-2 is a FGFR1 inhibitor (IC₅₀ is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer .

HY-16189

Elliptinium acetate NSC 264137; Celiptium	DNA Stain	Cancer
Elliptinium acetate (NSC 264137) is a DNA intercalating agent that is highly cytotoxic to L1 210 cells and covalently binds to nucleic acids from L1210 cells. Elliptinium acetate can be used in cancer research, particularly in metastatic breast cancer .

HY-126899

TPI-287	Microtubule/Tubulin	Cancer
TPI-287, a blood-brain barrier-permeable microtubule stabilizer, can significantly reduce metastatic colonization of breast cancer in the brain .

HY-P9912

Pertuzumab 5+ Cited Publications	EGFR	Cancer
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P9912A

Pertuzumab (anti-HER2)	EGFR	Cancer
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-148923

MC0704	STAT	Cancer
MC0704 is a *STAT3* inhibitor with an IC₅₀ value of 2.13 μM. MC0704 induces cell apoptosis and cell cycle arrest. MC0704 shows antitumor activity in mouse breast cancer models. MC0704 can be used for the research of metastatic triple-negative breast cancer (mTNBC) .

HY-123918

JMS-17-2 10+ Cited Publications	CX3CR1	Endocrinology Cancer
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC₅₀ of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells .

HY-123918A

JMS-17-2 hydrochloride	CX3CR1	Endocrinology Cancer
JMS-17-2 hydrochloride is a potent and selective CX3CR1 antagonist with an IC₅₀ of 0.32 nM. JMS-17-2 hydrochloride impairs metastatic seeding and colonization of breast cancer cells .

HY-112596A

H3B-6545 hydrochloride 3 Publications Verification	Estrogen Receptor/ERR	Cancer
H3B-6545 hydrochloride is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer .

HY-112596

H3B-6545 3 Publications Verification	Estrogen Receptor/ERR	Cancer
H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer .

HY-P9974

Vantictumab OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-18643

TZ9 2 Publications Verification	E1/E2/E3 Enzyme Apoptosis	Cancer
TZ9 is a selective Rad6 inhibitor. TZ9 inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin, induces G2-M arrest and apoptosis, and inhibits the proliferation and migration of metastatic human breast cancer cells .

HY-146684

HDAC-IN-36	HDAC Autophagy Apoptosis	Cancer
HDAC-IN-36 (compound 23 g) is an orally active and potent HDAC (histone deacetylase) inhibitor, with an IC₅₀ of 11.68 nM (HDAC6). HDAC-IN-36 promotes apoptosis, autophagy and suppresses migration. HDAC-IN-36 shows anti-tumor and anti-metastatic activity, and can be used for breast cancer research .

HY-147522

ADG-2e	Bacterial Antibiotic	Infection Cancer
ADG-2e is a potent antibacterial agent with MICs of 16, 4, 2, and 2 μg/mL for E. coli [KCTC 1682], P. aeruginosa [KCTC 1637], B.subtilis [KCTC 3068], and S. aureus [KCTC 1621], respectively. ADG-2e shows anti-metastatic activity against breast cancer cells .

HY-146516

Anticancer agent 42	MDM-2/p53 Apoptosis Reactive Oxygen Species	Cancer
Anticancer agent 42 (compound 10d) is an orally active anticancer agent, and shows a potent antitumor activity against MDA-MB-231 cell with an IC₅₀ of 0.07 μM. Anticancer agent 42 can exert its anticancer activity by activating apoptotic pathway and p53 expression. Anticancer agent 42 can be used to study metastatic breast cancer .

HY-157231A

HC-5404-Fu	PERK	Cancer
HC-5404-Fu is a PERK inhibitor with an antitumor activity. HC-5404-Fu inhibits endoplasmic reticulum stress response signalling. HC-5404-Fu sensitizes renal cell carcinoma cells to vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKIs). HC-5404-Fu is promising for research of renal cell carcinoma, gastric cancer, metastatic breast cancer, small cell lung cancer, and other solid tumors .

HY-114169

WRG-28	Discoidin Domain Receptor	Inflammation/Immunology Cancer
WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor, with an IC₅₀ of 230 nM. WRG-28 inhibits tumor invasion, migration and tumor-supporting effects of cancer-associated fibroblasts (CAFs). WRG-28 inhibits metastatic breast tumor cell colonization in the lungs. WRG-28 also shows good activity of relieving rheumatoid arthritis in CAIA model of mice .

HY-161778

ZG-126	HDAC VD/VDR	Inflammation/Immunology Cancer
ZG-126 is an agonist for vitamin D receptor (VDR) and an inhibitor for histone deacetylase (HDAC) (IC₅₀=0.63-67.6 μM). ZG-126 exhibits cytotoxicity in cancer cells MDA-MB-231 and 4T1. ZG-126 exhibits antitumor and anti-metastatic efficacy against melanoma and triple-negative breast cancer (TNBC) in mouse models. ZG-126 also exhibits anti-inflammatory activity, through the reduction of macrophage infiltration and immunosuppressive M2-polarization .

HY-144307

Aurora A/PKC-IN-1	Aurora Kinase PKC	Cancer
Aurora A/PKC-IN-1 (Compound 2e) is a potent dual inhibitor of Aurora A (AurA) and PKC (α, β1, β2, and θ) kinases with IC₅₀s of 6.9 nM and 16.9 nM for AurA and PKCα, respectively. Aurora A/PKC-IN-1 has antiproliferative activity in breast cancer cells and antimetastatic activity .

HY-136255

Camizestrant 5 Publications Verification AZD-9833	Estrogen Receptor/ERR	Cancer
Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of ER ⁺ HER2-advanced breast cancer .

HY-103490

Takinib 20+ Cited Publications EDHS-206	MAP3K Apoptosis	Infection Inflammation/Immunology Cancer
Takinib (EDHS-206) is an orally active and selective TAK1 inhibitor (IC₅₀=9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib is an inhibitor of autophosphorylated TAK1 that non-competitively binds within the ATP binding pocket. Takinib induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is also a P. falciparum protein kinase 9 (PfPK9) inhibitor (K_D(app) of 0.46 μM) .

HY-15319

AMG 487 20+ Cited Publications	CXCR	Inflammation/Immunology Endocrinology Cancer
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC₅₀s of 8.0 and 8.2 nM, respectively .

HY-P99630

Gancotamab MM-302	EGFR	Cancer
Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .

HY-15319A

(±)-AMG 487	CXCR	Cancer
(±)-AMG 487 is a racemate of AMG 487. AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC₅₀s of 8.0 and 8.2 nM, respectively .

HY-118762

KGP94	Cathepsin	Cancer
KGP94 is a selective inhibitor of cathepsin L with an IC₅₀ of 189 nM . KGP94 inhibits migration and invasion of metastatic carcinoma and shows low cytotoxicity (GI₅₀=26.9 µM) against various human cell lines .

Cat. No.	Product Name

HY-L074

Anti-Breast Cancer Compound Library	2,412 compounds
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 2,412 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Anti-Breast Cancer Compound Library

2,412 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,412 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Target	Research Area